Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gepotidacin DDI and PK Study in Healthy Adults
NCT04493931Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gepotidacin in bacterial infection (5 arms), sponsored by GSK. Primary endpoints: Maximum Observed Concentration at 60 hours, Time to Reach Maximum Observed Concentration and 8 more. Started Aug 2020; status: completed.
02
Drugs
gepotidacin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT04493931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493931.